Trexquant Investment LP Takes $2.47 Million Position in Edwards Lifesciences Corporation $EW

Key Points

• Trexquant Investment LP has acquired a new stake in Edwards Lifesciences Corporation, purchasing 34,108 shares valued at approximately $2.47 million in the first quarter.
• Several institutional investors, including Nuveen LLC and Jennison Associates LLC, have significantly increased their holdings in Edwards Lifesciences, indicating strong institutional interest in the company.
• Analysts have raised their price targets for Edwards Lifesciences, with Deutsche Bank setting a new target of $94.00 and BTIG Research upgrading their rating to "buy" with a price objective of $100.00.

Trexquant Investment LP acquired a new position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 34,108 shares of the medical research company's stock, valued at approximately $2,472,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Quantbot Technologies LP bought a new stake in Edwards Lifesciences during the 1st quarter valued at approximately $26,000. Vega Investment Solutions purchased a new stake in shares of Edwards Lifesciences in the 4th quarter worth $27,000. SouthState Corp purchased a new stake in shares of Edwards Lifesciences in the 1st quarter worth $27,000. Global X Japan Co. Ltd. lifted its stake in shares of Edwards Lifesciences by 116.1% during the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after purchasing an additional 216 shares during the last quarter. Finally, Tradewinds Capital Management LLC raised its stake in Edwards Lifesciences by 102.5% in the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after buying an additional 205 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently weighed in on EW. Daiwa America raised Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 29th. Canaccord Genuity Group lifted their price target on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock a "hold" rating in a research report on Friday, July 25th. Citigroup reiterated a "buy" rating and set a $95.00 price objective (up from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Royal Bank Of Canada upped their price objective on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Finally, Robert W. Baird increased their price target on shares of Edwards Lifesciences from $78.00 to $79.00 and gave the stock a "neutral" rating in a research report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has an average rating of "Moderate Buy" and a consensus target price of $85.90.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 4,114 shares of the firm's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,014 shares of company stock valued at $1,698,844 over the last three months. Corporate insiders own 0.34% of the company's stock.

Edwards Lifesciences Price Performance

EW stock traded down $1.06 during midday trading on Monday, reaching $79.88. The company had a trading volume of 1,620,833 shares, compared to its average volume of 4,441,340. The firm has a 50-day moving average price of $78.77 and a 200-day moving average price of $75.21. Edwards Lifesciences Corporation has a 1 year low of $64.00 and a 1 year high of $83.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The company has a market capitalization of $46.90 billion, a P/E ratio of 11.50, a P/E/G ratio of 3.90 and a beta of 1.07.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the prior year, the firm posted $0.70 EPS. Edwards Lifesciences's revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.